Certified Diabetes Educator Practice Exam 2025 - Free Practice Questions and Study Resource.

The action of GLP-1 receptor agonists primarily includes decreasing gastric motility and promoting satiety. GLP-1, or glucagon-like peptide-1, is an incretin hormone that plays a significant role in glucose metabolism and appetite regulation. When GLP-1 is activated, it slows down how quickly food leaves the stomach, leading to prolonged feelings of fullness, or satiety, after eating. This effect is particularly beneficial for individuals with type 2 diabetes, as it helps control blood sugar levels by preventing rapid rises in glucose after meals.

The other options do not accurately reflect the mechanism of GLP-1 receptor agonists. Glycogenolysis and gluconeogenesis are processes that increase blood sugar levels, which is contrary to the action of GLP-1 receptor agonists that help lower blood sugar. Enhancing glucagon secretion would also lead to increased glucose levels, which does not align with the glucose-lowering effects of these agents. Lastly, increasing lipid absorption in the intestines is not a function associated with GLP-1 receptor agonists; rather, they focus on managing blood glucose while also impacting weight loss positively.